Propanc Biopharma (PPCB) Non-Current Assets (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Non-Current Assets of $7.4 million for Q4 2025, up 12129.12% year-over-year from N/an in Q4 2024, and down 19.62% quarter-over-quarter from $9.2 million in Q3 2025.
Propanc Biopharma (PPCB) Non-Current Assets (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Non-Current Assets for 14 consecutive years, with $7.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 12129.12% year-over-year to $7.4 million; the TTM figure through Dec 2025 stood at $40.7 million (up 23274.66% YoY), while the FY2025 annual figure was $11.3 million, up 23936.72% from the prior year.
- Non-Current Assets eased to $7.4 million in Q4 2025 per PPCB's latest filing, from $9.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.8 million in Q1 2025 and bottomed at $5757.0 in Q3 2021.
- Historically, Non-Current Assets has averaged $2.1 million across 5 years, with a median of $44517.0 in 2024.
- Annual changes were most pronounced in 2021 — Non-Current Assets slumped 77.95% — and 2025, when it soared 52147.77%.
- Propanc Biopharma's Non-Current Assets stood at $25299.0 in 2021, then soared by 112.64% to $53796.0 in 2022, then sank by 42.22% to $31083.0 in 2023, then surged by 94.8% to $60549.0 in 2024, then jumped by 12129.12% to $7.4 million in 2025.
- Business Quant data shows PPCB's Non-Current Assets at $7.4 million in Q4 2025, $9.2 million in Q3 2025, and $11.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 7.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 9.21 Mn |
| Jun 30, 2025 | 11.28 Mn |
| Mar 31, 2025 | 12.79 Mn |
| Dec 31, 2024 | 60,549.00 |
| Sep 30, 2024 | 42,110.00 |
| Jun 30, 2024 | 46,924.00 |
| Mar 31, 2024 | 24,482.00 |
| Dec 31, 2023 | 31,083.00 |
| Sep 30, 2023 | 34,567.00 |
| Jun 30, 2023 | 41,289.00 |
| Mar 31, 2023 | 47,167.00 |
| Dec 31, 2022 | 53,796.00 |
| Sep 30, 2022 | 56,392.00 |
| Jun 30, 2022 | 66,621.00 |
| Mar 31, 2022 | 24,954.00 |
| Dec 31, 2021 | 25,299.00 |
| Sep 30, 2021 | 5,757.00 |
| Jun 30, 2021 | 6,505.00 |
| Mar 31, 2021 | 9,525.00 |